FDX1 and colon adenocarcinoma: These findings suggest that the combined use of elesclomol and FDX1 overexpression holds great promise in the treatment of COAD, filling the research gap regarding the enhancement of cuproptosis in COAD through the combination of FDX1 and elesclomol.